PortfoliosLab logo
bluebird bio, Inc. (BLUE)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US09609G1004

CUSIP

09609G100

IPO Date

Jun 19, 2013

Highlights

Market Cap

$34.27M

EPS (TTM)

-$24.84

PEG Ratio

0.32

Total Revenue (TTM)

$65.23M

Gross Profit (TTM)

$1.72M

EBITDA (TTM)

-$108.13M

Year Range

$3.48 - $4.00

Target Price

$6.50

Short %

5.21%

Short Ratio

0.99

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period


BLUE

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-0.86%

1M

8.72%

6M

-2.74%

1Y

11.65%

5Y*

15.28%

10Y*

10.67%

*Annualized

Monthly Returns

The table below presents the monthly returns of BLUE, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-11.84%-11.84%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of BLUE is 14, meaning it’s performing worse than 86% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of BLUE is 1414
Overall Rank
The Sharpe Ratio Rank of BLUE is 2121
Sharpe Ratio Rank
The Sortino Ratio Rank of BLUE is 1616
Sortino Ratio Rank
The Omega Ratio Rank of BLUE is 1616
Omega Ratio Rank
The Calmar Ratio Rank of BLUE is 44
Calmar Ratio Rank
The Martin Ratio Rank of BLUE is 1313
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for bluebird bio, Inc. (BLUE) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


There isn't enough data available to calculate the Sharpe ratio for bluebird bio, Inc.. This metric is based on the past 12 months of trading data. Please check back later for updated information.


Loading data...

Dividends

Dividend History


bluebird bio, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the bluebird bio, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the bluebird bio, Inc. was 11.84%, occurring on May 9, 2025. The portfolio has not yet recovered.

The current bluebird bio, Inc. drawdown is 11.84%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-11.84%May 6, 20254May 9, 2025

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of bluebird bio, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of bluebird bio, Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 54.9% positive surprise.


-15.00-10.00-5.000.00AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober
-2.84
-6.30
Actual
Estimate

Valuation

The Valuation section provides an overview of how bluebird bio, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for BLUE compared to other companies in the Biotechnology industry. BLUE currently has a PEG ratio of 0.3. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for BLUE relative to other companies in the Biotechnology industry. Currently, BLUE has a P/S ratio of 0.4. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for BLUE in comparison with other companies in the Biotechnology industry. Currently, BLUE has a P/B value of 0.7. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items